Evidence that naloxonazine produces prolonged antagonism of central delta opioid receptor activity in vivo.
Intracerebroventricular (i.c.v.) administrations of the postulated mu 1 opioid receptor antagonist naloxonazine produced an increase in the frequency of urinary bladder contractions recorded isometrically in the anesthetized rat. This substance also antagonized the inhibition of spontaneous bladder contractions produced by submaximal i.c.v. doses of the highly selective mu opioid agonist [D-Ala2-MePhe4,Gly-(ol)5]enkephalin (DAGO) and the delta opioid agonist [D-Pen2,D-Pen5]enkephalin (DPDPE). The antagonism of DAGO was reversible but that of DPDPE lasted up to 30 h. These data suggest that endogenous opioids are involved in the central control of bladder motility and that naloxonazine is a long-lasting delta opioid receptor antagonist.
D000818:Animals; D002490:Central Nervous System / Q000187:drug effects* / Q000502:physiology; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D020881:Enkephalin, D-Penicillamine (2,5)-; D004745:Enkephalins / Q000037:antagonists & inhibitors; D005260:Female; D009270:Naloxone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009433:Neural Inhibition; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects* / Q000502:physiology; D017465:Receptors, Opioid, delta; D001743:Urinary Bladder / Q000294:innervation* / Q000502:physiology
D004745:Enkephalins; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009270:Naloxone; C034643:naloxonazine; D020881:Enkephalin, D-Penicillamine (2,5)-